Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Invivo Therapeutics Holdings Corp announces new chief executive officer


Monday, 23 Dec 2013 04:30pm EST 

Invivo Therapeutics Holdings Corp:Says the appointment of Mark D. Perrin as Chief Executive Officer, effective Jan. 6, 2014.Says upon his appointment, Mr. Perrin will also become a member of the Board of Directors. 

Company Quote

2.97
-0.03 -1.00%
31 Mar 2015